Company Profile

RxBio Inc (AKA: RxBio Holdings)
Profile last edited on: 5/6/16      CAGE: 4CJP9      UEI: DB9LSMAHKNJ8

Business Identifier: protection against lethal whole-body radiation, damage to the GI tract, chemotherapy and various toxins
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

Po Box 5389
Johnson City, TN 37602
   (423) 928-3330
Location: Single
Congr. District: 01
County: Washington

Public Profile

RxBio was formed around novel and proprietary small-molecule technology developed at the University of Tennessee Health Science Center (UTHSC) in Memphis and licensed from the University of Tennessee Research Foundation (UTRF). RxBio's technology platform is broadly based and includes includes its lead compoun, Rx100. Recent murine and nonhuman primate studies (required under FDA’s “Animal Rule” for demonstration of safety and efficacy) have confirmed Rx100’s ability to dramatically improve survival after high doses of irradiation. The company also is working on treatment of secretory diarrhea, prevention of NSAID-induced stomach erosions (e.g., aspirin), compounds for treatment and prevention of hematological-ARS, anti-inflammatory compounds, a compound for treatment of glioma – a universally fatal form of brain cancer RxBio Holdings, Inc. operates as a biotechnology company developing products that protect against lethal whole-body radiation, and against damage to the GI tract due to radiation, chemotherapy and various toxins. The company develops cancer agents and those that block plaque build-up in blood

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2020 1 NIH $252,128
Project Title: Targeted Therapies for the Treatment of GI-ARS Diarrhea
2015 1 NIH $222,829
Project Title: The Anti-Diarrheal Potential of a Lpa Analog Rx100
2015 1 NIH $297,087
Project Title: Development of Rx100 as Novel Medical Countermeasure for Acute Radiation Syndrome
2011 1 NIH $194,797
Project Title: Tas::75 0849::Tas
2008 1 NIH $99,977
Project Title: Development Of An Lpa Receptor Modulator Rx100 As A Radioprotectant

Key People / Management

  Shannon Mccool -- President; Chairman; CEO

  Wenlin Deng

  Veeresa Gududuru

  Roy Hoff

  Michael Jabbour

  Samina Khan

  Martin McCool

  Alan Rosenthal

  Gabor J Tigyi

  Joseph Welch

  Wilma Jean Wills